The 2 major findings of this study can be summarized as follows: (1) use of GLP-1 receptor agonists in patients with diabetes and stage 5 CKD or EKSD was associated with lower all-cause mortality compared with use of DPP-4 inhibitors and (2) use of GLP-1 receptor agonists was associated with lower sepsis- and infection-related mortality compared with use of DPP-4 inhibitors. Here, GLP1R is linked to diabetes mellitus.